Amgen

Open: 223.08 Close: 221.22 Change: -1.86

Can you guess what an AI found about Amgen Company Inc.

How much time have you spent trying to decide whether investing in Amgen? Many investors start with the dream of being free. They expect to find on the stock market an option to have time to develop their own interests and hobbies. That is, a way to escape a 9 to 5 job. However, investment is complex and investors end up spending whole days (and nights) trying to figure out which the right stock to invest is. The dream of stock investing becomes the nightmare of facing infinity amounts of information. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Amgen are: Amgen, present, …

Concept Map

Semantic Network

Stock Summary

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's products include Enbrel, Prolia, Xgeva, Otezla, Aranesp, and Repatha..

Today's Summary

Federal Trade Commission expected to introduce lawsuit to block $27.8 billion merger with Amgen. Johnson & Johnson settled lawsuit over Amgens proposed biosimilar version of J&Js Stelara. Amgen will present at the TD Cowen 4th Annual Oncology Innovation Summit at 11:00 a.m. on May 26, 2023. Jefferies managing director Michael Yee expects Amgens Horizon Therapeutics deal to go through. $1000 invested in Amgen 15 years ago would be worth today.

Today's News

Amgen Inc. (AMGN) Latest Stock News | Seeking Alpha. The FTCs challenge to Amgen inc. stock falls t Tuesday, underperforms market. Federal Trade Commission (FTC) is expected to introduce a lawsuit to block the proposed $27.8 billion merger with Amgen (NASDAQ:AMGN) Johnson & Johnson has settled its lawsuit over Amgens proposed biosimilar version of J&Js Stelara. The Supreme Court clearly disapproved of functional claims, particularly in the antibody context, but did not foreclose genus claims. Despite recent advances, aspects of antibody science remain unpredictable. Amgen (NASDAQ:AMGN) announced the presentation of new data from the CodeBreaK clinical trial program, the most comprehensive global development program. The biotechs yield is near an all-time high. The CodeBreaK clinical development program for sotorasib is designed to study patients with an advanced solid tumor with the KRAS  G12C mutation. Amgen is progressing the largest and broadest global KRAS G12C  inhibitor development program with unparalleled speed. Amgen has submitted MAAs in Argentina, Colombia, Kuwait, Macao, Malaysia, Mexico, Russia, Saudi Arabia, Thailand and Turkey. Amgen presents new lumakras® (sotorasib) codebreak 200 cns data at asco 2023. Amgen presents new lumakras® (sotorasib) codebreak 200 cns data at asco 2023. Data from SCARLET, an Amgen funded investigator study sponsored by the West Japan Oncology Group, will be presented June 6. Amgen presents new lumakras® (sotorasib) codebreak 200 cns data at asco 2023. Data from SCARLET, an Amgen funded investigator study sponsored by the West Japan Oncology Group, will be presented on June 6. Amgen presents new lumakras® (sotorasib) codebreak 200 cns data at asco 2023. LUMAKRAS shows improved PFS vs Docetaxel across key co-Alteration Subgroups in the Phase 3 CodeBreaK 200 study. Amgen presents new lumakras® (sotorasib) codebreak 200 cns data at asco 2023. Data from SCARLET, an Amgen funded investigator study sponsored by the West Japan Oncology Group, will be presented. Amgen presents new data from CodeBreaK clinical trial program at American Society of Clinical Oncology (ASCO) Annual Meeting taking place June 2-6 in Chicago. Data from SCARLET, an Amgen funded investigator study sponsored by the West Japan Oncologist Group, will be presented June 6. Amgen presents new lumakras® (sotorasib) codebreak 200 cns data at asco 2023. Data from SCARLET, an Amgen funded investigator study sponsored by the West Japan Oncology Group, will be presented on June 6. Amgen presents new data from the CodeBreaK clinical trial program at the American Society of Clinical Oncology (ASCO) Annual Meeting taking place June 2-6 in Chicago. LUMAKRAS shows improved PFS vs Docetaxel across Key Co-Alteration Subgroups. Amgen presents new lumakras® (sotorasib) codebreak 200 cns data at asco 2023. Vectibix® Prescribing Information includes Boxed Warning. Amgen has submitted MAAs in Argentina, Colombia, Kuwait, Macao, Malaysia, Mexico, Russia, Saudi Arabia, Thailand and Turkey. Amgen scientists & researchers are in Washington, D.C. This week, scientists and researchers from Amgen will speak with policymakers in Washington. Today Amgen announced the presentation of the new presentation of its new clinical data for its #BreGASA cell. Amgen has boasted a transformative regulatory environment across the regulatory space, and life sciences is the latest industry receiving scrutiny from regulators. Will the FTCs Amgen Suit against Amgenite Future Pharmaceuticals Ignite future Pharmaceuticals? Amgen will present new scientific and clinical research at the American Society of Clinical Oncology (ASCO) Annual Meeting, taking place from June 2-6. Amgen is currently investigating tarlatamab in multiple trials, including DeLLphi-301, a potentially registrational Phase 2 study in heavily pretreated SCLC. In todays podcast, Im joined by Jonathan Graham, the executive vice president, general counsel, and secretary. Amgen share price has underperformed the S&P500 Index by -13.88% over the past year. Amgen pay a total dividend of $7.795 , Amgen currently has a trailing dividend of 3.58%. Analysts covering Amgen currently have a consensus Earnings Per Share (EPS) forecast of $17.82 for the next financial year. Amgen PE ratio based on its reported earnings over the past 12 months is 12.15.

Stock Profile

"Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. It has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and research and development collaboration with Neumora Therapeutics, Inc. and Plexium, Inc. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California."

Keywords

This document will help you to evaluate Amgen without reading an infinite amount of sources. Relying only on stock quotes or prices to make investment decisions is a mistake. Analyzing and observing stock charts, highs and lows and other numerical data does not allow to evaluate the real value of a company. Stock quotes and prices are the result of underlying characteristics of a company and of events and news happening around them. For this reason, investing must be based on information, not numbers. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Amgen are: Amgen, present, new, data, sotorasib, study, lumakras, and the most common words in the summary are: amgen, stock, news, market, new, state, court, . One of the sentences in the summary was: Amgen will present at the TD Cowen 4th Annual Oncology Innovation Summit at 11:00 a.m. Other searches related to this term that the AI found were: stockmarketlive, livestock, stockmarketforbeginners, thestockmarket, stockmarkettoday, stockmarkettrading, stockmarketstocks, todaystockmarket, thestockmarket, marketnews, stockmarketnews, whatisstockmarket, usstockmarket, stockmarketopen. #amgen #stock #news #market #new #state #court.